Makker V, et al. - In patients with metastatic endometrial carcinoma recruited from 11 centers in the US, researchers evaluated the therapeutic efficacy of the combination of lenvatinib (a multikinase inhibitor of VEGFR1, VEGFR2, and VEGFR3, and other receptor tyrosine kinases) plus pembrolizumab. They administered 20 mg oral lenvatinib daily plus 200 mg intravenous pembrolizumab every 3 weeks to patients aged 18 years or older with metastatic endometrial cancer (unselected for microsatellite instability or PD-L1), and an Eastern Cooperative Oncology Group performance status of 0 or 1, who had no more than two previous systemic therapies, had measurable disease according to the immune-related Response Evaluation Criteria In Solid Tumors (irRECIST), and had a life expectancy of 12 weeks or longer. In patients with advanced recurrent endometrial cancer, anti-tumor activity of lenvatinib plus pembrolizumab was seen. Compared with safety profiles previously reported for lenvatinib and pembrolizumab monotherapies, a comparable safety profile was demonstrated in this study with lenvatinib plus pembrolizumab, other than an increased frequency of hypothyroidism. Overall, this combination therapy could be a novel possible treatment option for these patients.